Announcement of the resolution by the Board of Directors not to distribute dividends by the company, on behalf of major subsidiary Amaran Biotechnology, Inc.
2021.Apr.21
OBI-3424 completes its phase 1 safety evaluation and demonstrates its safety with no major concerns, proceeding to phase 2 as planned
2021.Apr.20
OBI Filed the Application of Phase III Human Clinical Study for the Active Cancer Immunotherapy OBI-822, Adagloxad Simolenin, to the Health Authority of Peru
2021.Apr.07
OBI’s application to initiate the Phase III clinical study of the active cancer immunotherapy OBI-822 (Adagloxad Simolenin) has been denied by the Ministry of Health, Argentina
2021.Mar.17
OBI filed the application to EMA for Phase III human clinical study of the active cancer immunotherapy OBI-822, Adagloxad Simolenin, in Spain, German, and Poland
2021.Mar.12
The Board of Directors resolved to hold 2021 Annual General Meeting
2021.Mar.12
Announcement of not Distributing Dividends in 2020
2021.Mar.12
Announcement of 2020 Consolidated Financial Report
2021.Mar.12
OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations of Mexico
2021.Feb.23
OBI licensed “OBI-858 Novel Botulinum Toxin Preparation” Intellectual Property Right of Global Aesthetic Medicine to OBIGEN Pharma, Inc.
